A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...